Skip to main navigation Skip to search Skip to main content

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

  • Matteo Perra
  • , Ines Castangia
  • , Matteo Aroffu
  • , Federica Fulgheri
  • , Rita Abi-Rached
  • , Maria Letizia Manca
  • , Hernán Cortés
  • , María Luisa Del Prado-Audelo
  • , Carla Nomura-Contreras
  • , Alejandra Romero-Montero
  • , Dietrich Büsselberg
  • , Gerardo Leyva-Gómez
  • , Javad Sharifi-Rad
  • , Daniela Calina
  • University of Cagliari
  • Instituto Nacional de Rehabilitación
  • Instituto Tecnologico de Estudios Superiores de Monterrey
  • Universidad Nacional Autónoma de México
  • Qatar Foundation
  • Craiova University of Medicine and Pharmacy

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due to severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights the anticancer activity of maytansinoids, with a focus on AMCs designed to target cancer cells specifically. Preclinical and clinical studies show that AMCs, including FDA-approved drugs like Kadcyla and Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry and payload design. Ongoing research aims to enhance the safety and efficacy of AMCs, integrate nanotechnology for drug delivery, and identify novel therapeutic targets. These advancements hold potential to transform maytansinoid-based cancer treatments in the future.

Original languageEnglish
Article number73
JournalDiscover Oncology
Volume16
Issue number1
DOIs
StatePublished - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antibody-maytansinoid conjugates
  • Anticancer studies
  • Maytansine
  • Maytansinoid-based therapies
  • Microtubules polymerization inhibitors
  • Natural compounds

Fingerprint

Dive into the research topics of 'Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems'. Together they form a unique fingerprint.

Cite this